Michael J. Deninger

Michael J. Deninger

Auto-generated profile, based on publicly available information

Michael J. Deninger

Towncrest Pharmacy. Iowa City, IA (United States).

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Research in Social and Administrative Pharmacy
Verified
Journal Article
Closed access
AGAmber Goedken
Amber Goedken
CBChristine M. Butler
Christine M. Butler
RMRandal P. McDonough
Randal P. McDonough
MDMichael J. Deninger
Michael J. Deninger
WDWilliam R. Doucette
William R. Doucette

1 November 2017 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
WDWilliam R. Doucette
William R. Doucette
RMRandal P. McDonough
Randal P. McDonough
FHFischer Herald
Fischer Herald
AGAmber Goedken
Amber Goedken
JFJenn Funk
Jenn Funk
MDMichael J. Deninger
Michael J. Deninger

31 December 2000 in Experimental and Clinical Endocrinology & Diabetes
Verified
Journal Article
Closed access
MKM. Koch
M. Koch
KRK. Rett
K. Rett
EME. Maerker
E. Maerker
AVA. Volk
A. Volk
KHK. Haist
K. Haist
HHH. U. Häring
H. U. Häring
The peroxisome proliferator activated receptors-γ (PPARγ) belong to the superfamily of nuclear transcription factors acting as master genes regulating events in adipocyte differentiation. Thus, PPARγ is a candidate gene for affecting insulin sensitivity and the pathogenesis of insulin resistance. PPARs trigger endocrine response of two important adipose tissue-derived signalling factors, leptin and tumor necrosis factor-α. Leptin is the afferent signal in a negative feedback loop regulating adipose tissue mass and energy balance. It generates insulin-like signals for glucose transport and glycogen synthesis via leptin receptors and the PI3-kinase and could, therefore, play a role as a mediator of obesity-related insulin resistance. Recently, a silent substitution in the coding sequence of the PPARγ2 gene, leading to the substitution of a C by a T in exon 6 (nt 161), was described. In a recent study, it was proposed that mutations in PPARγ could play a role in individuals who are at increased risk for developing obesity and type 2 diabetes mellitus by influencing leptin levels. We therefore examined the prevalence of the CACHis → CATHis mutation in non-diabetic first degree relatives of subjects with type 2 diabetes to determine a possible association of this mutation to leptin levels and insulin sensitivity. 138 probands were characterised by oral glucose tolerance tests, euglycemic-hyperinsulinemic glucose-clamp and by measuring leptin levels. We found 93 (67.4%) probands without the CACHis → CATHis substitution and 45 heterozygotes (36.6%). When the whole group was analysed for an association of the mutation with plasma leptin concentration and insulin sensitivity, no statistical significance could be demonstrated. Independently of the mutation, leptin levels were significantly (p < 0.001) higher in female subjects. Abbreviations: FDR first degree relatives; ISR insulin secretion rate; MCR metabolic clearance rate; oGTT oral glucose tolerance test; PPAR peroxisome proliferator activated receptors; Pro Prolin; Ala Alanin

30 June 2019 in Pharmacy Practice
Verified
Journal Article
Open access
PDF file
RFRebecca M. Fitzpatrick
Rebecca M. Fitzpatrick
MWMatthew Witry
Matthew Witry
WDWilliam Doucette
William Doucette
KKKelly Kent
Kelly Kent
MDMichael J. Deninger
Michael J. Deninger
SVStevie Veach
Stevie Veach
Pharmacy Practice is a free full-text journal with a scope on the practice of pharmacy. Pharmacy Practice covers pharmaceutical care, social pharmacy, pharmacy education, process and outcome research, health promotion and education, health informatics, pharmacoepidemiology

20 August 2018 in Pharmacy
Verified
Journal Article
Open access
PDF file
AGAmber Goedken
Amber Goedken
SHSharon Huang
Sharon Huang
RMRandy McDonough
Randy McDonough
MDMichael J. Deninger
Michael J. Deninger
WDWilliam Doucette
William Doucette
Community pharmacists performing Continuous Medication Monitoring (CoMM) systematically monitor each new prescription and refill dispensed for medication-related problems. The objectives for this study were to describe medication-related problems identified through CoMM and drug classes involved in problems. This 12-month pilot study used dispensing and clinical records from a single independent U.S. community pharmacy. Clinical records contain medication-related problems documented by the pharmacists. Problems identified for patients filling at least one prescription at the pharmacy and having at least one medication-related problem during the study period were included. A total of 8439 medication-related problems were identified for 1566 patients, an average of 5.4 problems per patient. Over 63% of problems were nonadherence. The drug class most often involved in problems was the central nervous system and analgesic class. Community pharmacists performing CoMM identified medication-related problems that might otherwise have gone undetected.

1 June 2018 in Research in Social and Administrative Pharmacy
Verified
Journal Article
Closed access
MWMatthew Witry
Matthew Witry
RPRachel Parry
Rachel Parry
RMRandy McDonough
Randy McDonough
MDMichael Deninger
Michael Deninger